This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MOACYR E. ALVARO, M.D.

Arch Ophthal. 1943;29(4):615-632.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

According to Long and associates,¹ ocular involvement is a rare complication in therapy with sulfonamide compounds. As far as could be determined, ocular complications, although they indicated the advisability of stopping the treatment, did not have the same mandatory importance as other complications, such as hepatitis, leukopenia with granulocytopenia, acute agranulocytosis and hemolytic anemia.

Nevertheless, the data found in the ophthalmologic literature and occasionally elsewhere regarding ocular involvement as a consequence of the use of sulfonamide compounds are numerous enough to suggest the necessity for a systematic study of the subject.

PENETRATION AND DISTRIBUTION OF SULFONAMIDE COMPOUNDS IN THE EYE

Sulfonamide compounds given orally reach the eye as soon as fifteen minutes after they are taken (Bellows and Chinn²) and arrive at their maximum concentration in the ocular tissues about the sixth hour. They are found in the tears (Venco³) and can still be traced in the . . . [Full Text PDF of this Article]

Author Affiliations
SÃO PAULO, BRAZIL

From the Department of Ophthalmology, Escola Paulista de Medicina.

Footnotes
Read before the Section on Ophthalmology at the Ninety-Third Annual Session of the American Medical Association, Atlantic City, N. J., June 10, 1942.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?